Cargando…

Correction: First use of cenerimod, a selective S1P(1) receptor modulator, for the treatment of SLE: a double-blind, randomised, placebo-controlled, proof-of-concept study

Detalles Bibliográficos
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2020
Materias:	Correction
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7228551/ https://www.ncbi.nlm.nih.gov/pubmed/32381629 http://dx.doi.org/10.1136/lupus-2019-000354corr1

Ejemplares similares

First use of cenerimod, a selective S1P(1) receptor modulator, for the treatment of SLE: a double-blind, randomised, placebo-controlled, proof-of-concept study
por: Hermann, Viktoria, et al.
Publicado: (2019)

Attenuation of murine sclerodermatous models by the selective S1P(1) receptor modulator cenerimod
por: Kano, Miyu, et al.
Publicado: (2019)

Cenerimod, a novel selective S1P(1) receptor modulator with unique signaling properties
por: Piali, Luca, et al.
Publicado: (2017)

Relieving acute pain (RAP) study: a proof-of-concept protocol for a randomised, double-blind, placebo-controlled trial
por: Colloca, Luana, et al.
Publicado: (2019)

An Investigation of Levetiracetam in Alzheimer’s Disease (ILiAD): a double-blind, placebo-controlled, randomised crossover proof of concept study
por: Sen, Arjune, et al.
Publicado: (2021)

Preclinical to clinical translation of cenerimod, a novel S1P(1) receptor modulator, in systemic lupus erythematosus
por: Strasser, Daniel S, et al.
Publicado: (2020)

Double-blind, placebo-controlled, proof-of-concept trial of bexarotene Xin moderate Alzheimer’s disease
por: Cummings, Jeffrey L., et al.
Publicado: (2016)

11β-HSD1 inhibition in men mitigates prednisolone-induced adverse effects in a proof-of-concept randomised double-blind placebo-controlled trial
por: Othonos, Nantia, et al.
Publicado: (2023)

Pharmacokinetics, Pharmacodynamics, Tolerability, and Food Effect of Cenerimod, a Selective S1P(1) Receptor Modulator in Healthy Subjects
por: Juif, Pierre-Eric, et al.
Publicado: (2017)

Lack of Effect of Cenerimod, a Selective S1P(1) Receptor Modulator, on the Pharmacokinetics of a Combined Oral Contraceptive
por: Juif, Pierre-Eric, et al.
Publicado: (2022)

Correction to: A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer’s disease with lecanemab, an anti-Aβ protofibril antibody
por: Swanson, Chad J., et al.
Publicado: (2022)

Correction: Aspartame Sensitivity? A Double Blind Randomised Crossover Study
Publicado: (2015)

Pharmacokinetics and Pharmacodynamics of Cenerimod, A Selective S1P(1)R Modulator, Are Not Affected by Ethnicity in Healthy Asian and White Subjects
por: Juif, Pierre‐Eric, et al.
Publicado: (2020)

Minocycline and aspirin in the treatment of bipolar depression: a protocol for a proof-of-concept, randomised, double-blind, placebo-controlled, 2×2 clinical trial
por: Savitz, Jonathan, et al.
Publicado: (2012)

The use of equine chondrogenic‐induced mesenchymal stem cells as a treatment for osteoarthritis: A randomised, double‐blinded, placebo‐controlled proof‐of‐concept study
por: Broeckx, S. Y., et al.
Publicado: (2019)

Cenerimod, a selective S1P(1) receptor modulator, improves organ-specific disease outcomes in animal models of Sjögren’s syndrome
por: Gerossier, Estelle, et al.
Publicado: (2021)

Ciclosporin to Protect Renal function In Cardiac Surgery (CiPRICS): a study protocol for a double-blind, randomised, placebo-controlled, proof-of-concept study
por: Ederoth, Per, et al.
Publicado: (2016)

Risankizumab, an IL-23 inhibitor, for ankylosing spondylitis: results of a randomised, double-blind, placebo-controlled, proof-of-concept, dose-finding phase 2 study
por: Baeten, Dominique, et al.
Publicado: (2018)

Publisher Correction: Accurate Detection of Dobutamine-induced Haemodynamic Changes by Kino-Cardiography: A Randomised Double-Blind Placebo-Controlled Validation Study
por: Hossein, Amin, et al.
Publicado: (2020)

A randomized, double-blind, placebo-controlled, proof-of-concept trial of creatine monohydrate as adjunctive treatment for bipolar depression
por: Toniolo, Ricardo Alexandre, et al.
Publicado: (2017)

Correction to: Selenium supplementation in patients with peripartum cardiomyopathy: a proof‑of‑concept trial
por: Karaye, Kamilu M., et al.
Publicado: (2021)

Correction: A Preliminary Randomized Double Blind Placebo-Controlled Trial of Intravenous Immunoglobulin for Japanese Encephalitis in Nepal
por: Rayamajhi, Ajit, et al.
Publicado: (2015)

Correction: Silymarin in non-cirrhotics with non-alcoholic steatohepatitis: A randomized, double-blind, placebo controlled trial
por: Navarro, Victor J., et al.
Publicado: (2019)

Correction: Acipimox in Mitochondrial Myopathy (AIMM): study protocol for a randomised, double-blinded, placebo-controlled, adaptive design trial of the efficacy of acipimox in adult patients with mitochondrial myopathy
por: Abouhajar, Alaa, et al.
Publicado: (2022)

Correction to: The FreeD module for the Lokomat facilitates a physiological movement pattern in healthy people – a proof of concept study
por: Aurich-Schuler, Tabea, et al.
Publicado: (2019)

Quetiapine augmentation of SRIs in treatment refractory obsessive-compulsive disorder: a double-blind, randomised, placebo-controlled study [ISRCTN83050762]
por: Carey, Paul D, et al.
Publicado: (2005)

Cannabidiol (CBD) and Δ(9)-tetrahydrocannabinol (THC) for chronic insomnia disorder (‘CANSLEEP’ trial): protocol for a randomised, placebo-controlled, double-blinded, proof-of-concept trial
por: Suraev, Anastasia, et al.
Publicado: (2020)

A randomised, double-blind, placebo-controlled, 24-week, phase II, proof-of-concept study of romilkimab (SAR156597) in early diffuse cutaneous systemic sclerosis
por: Allanore, Yannick, et al.
Publicado: (2020)

Correction: Vedolizumab in Japanese patients with ulcerative colitis: A Phase 3, randomized, double-blind, placebo-controlled study
por: Motoya, Satoshi, et al.
Publicado: (2019)

Correction: Surgical treatments for postamputation pain: study protocol for an international, double-blind, randomised controlled trial
por: Pettersen, Emily, et al.
Publicado: (2023)

Correction: Study protocol for a pilot, randomised, double-blinded, placebo controlled trial of perineural local anaesthetics and steroids for chronic posttraumatic neuropathic pain in the ankle and foot: the PREPLANS study
Publicado: (2016)

Correction: Postoperative intravenous parecoxib sodium followed by oral celecoxib post total knee arthroplasty in osteoarthritis patients (PIPFORCE): a multicentre, double-blind, randomised, placebo-controlled trial
Publicado: (2020)

Dasotraline for the Treatment of Attention-Deficit/Hyperactivity Disorder: A Randomized, Double-Blind, Placebo-Controlled, Proof-of-Concept Trial in Adults
por: Koblan, Kenneth S, et al.
Publicado: (2015)

Efficacy and Safety of ASP0819 in Patients with Fibromyalgia: Results of a Proof-of-Concept, Randomized, Double-Blind, Placebo-Controlled Trial
por: Arnold, Leslie M, et al.
Publicado: (2020)

Randomized Double-blind Placebo-controlled Proof-of-concept Trial of Resveratrol for Outpatient Treatment of Mild Coronavirus Disease (COVID-19)
por: McCreary, Marvin R., et al.
Publicado: (2021)

Randomized double-blind placebo-controlled proof-of-concept trial of resveratrol for outpatient treatment of mild coronavirus disease (COVID-19)
por: McCreary, Marvin R., et al.
Publicado: (2022)

Pyrotinib versus placebo in combination with trastuzumab and docetaxel as first line treatment in patients with HER2 positive metastatic breast cancer (PHILA): randomised, double blind, multicentre, phase 3 trial
Publicado: (2023)

Correction: SARS-CoV-2 vaccines in patients with SLE
Publicado: (2021)

Correction to: Nicotinamide riboside as a neuroprotective therapy for glaucoma: study protocol for a randomized, double-blind, placebo-control trial
por: Leung, Christopher Kai Shun, et al.
Publicado: (2022)

Correction: Prednisolone does not improve olfactory function after COVID-19: a randomized, double-blind, placebo-controlled trial
por: Schepens, Emma J. A., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_os19csj42u2jvaimcojur56fqh